Local Tolerability of AN2728 Topical Ointment, 2% in Sensitive Areas in Healthy Volunteers.

Trial Profile

Local Tolerability of AN2728 Topical Ointment, 2% in Sensitive Areas in Healthy Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Jun 2016

At a glance

  • Drugs Crisaborole (Primary)
  • Indications Atopic dermatitis; Psoriasis
  • Focus Adverse reactions
  • Sponsors Anacor Pharmaceuticals
  • Most Recent Events

    • 22 Jun 2016 Results published in the American Journal of Clinical Dermatology
    • 07 Feb 2012 Status changed from recruiting to completed, according to an Anacor Pharmaceuticals media release.
    • 06 Dec 2011 New source identified and integrated (Australian New Zealand Clinical Trials Registry; ACTRN12611001128987).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top